Kyverna Therapeutics’ Promising KYSA-8 Study and Strategic Plans Bolster Buy Rating
I'm PortAI, I can summarize articles.
Analyst Thomas Smith of Leerink Partners maintains a Buy rating on Kyverna Therapeutics, citing promising results from the KYSA-8 study for SPS patients. The study shows transformative outcomes with a favorable risk/benefit profile. Kyverna plans to submit a BLA for miv-cel by 2026, aiming for approval by 2027. Strategic plans and progress in other therapeutic areas bolster the investment case. Smith is a top analyst with a 47% average return.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments